Skip to main content
. 2017 May 19;6(6):1165–1172. doi: 10.1002/cam4.1054

Figure 1.

Figure 1

Cumulative risk of thromboembolic complications and bleeding complications in atrial fibrillation patients with and without a previous cancer diagnosis who used vitamin K antagonists (VKA) or non‐vitamin K antagonist oral anticoagulants (NOAC), Denmark, July 2004–December 2013.